Meningococcal carriage and immunity in western Burkina Faso, 2003

被引:5
作者
Yaro, Seydou
Traore, Yves
Tarnagda, Zekiba
Sangare, Lassana
NjanpopLafourcade, Berthe-Marie
Drabo, Aly
Findlow, Helen
Borrow, Raymond
Nicolas, Pierre
Gessner, Bradford D.
Mueller, Judith E.
机构
[1] Inst Pasteur, AMP, F-75724 Paris, France
[2] Ctr Muraz, Bobo Dioulasso, Burkina Faso
[3] Univ Ouagadougou, Ouagadougou, Burkina Faso
[4] Inst Res Sci Sante, Bobo Dioulasso, Burkina Faso
[5] Univ Yalgado Ouedraogo, Ctr Hosp, Ouagadougou, Burkina Faso
[6] Agcy Med Prevent, Paris, France
[7] Hlth Protect Agcy, Vaccine Evaluat Unit, Manchester, Lancs, England
[8] WHO Collaborat Ctr Ref & Res Meningococci, Inst Med Trop Serv Sante Armees, Marseille, France
关键词
Neisseria meningitidis; carriage; immunity;
D O I
10.1016/j.vaccine.2007.04.039
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A prospective carriage and serological study was conducted in Burkina Faso during the 2003 meningitis season, which was characterized by hyperendemic Neisseria meningitidis serogroup W135 (NmW135) and serogroup A (NmA) disease. Participants were evaluated five times at monthly intervals. In the presence of moderate NmW135 carriage, we found a low prevalence of putatively protective levels of specific immunoglobulin G (IgG) and serum bactericidal antibody (SBA) against NmW135. Specific IgG concentrations and SBA titers against NmA were relatively high in this recently vaccinated population, while no NmA carriage was detected. NmW135 carriage infrequently induced protective immunity against reference or homologous strains, while natural immunity against NmW135 was frequently lost. A vaccine that is effective against W135 will be beneficial for sub-Saharan Africa. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:A42 / A46
页数:5
相关论文
共 19 条
  • [1] Naturally-acquired immunity to Neisseria miningitidis group A
    Amir, J
    Louie, L
    Granoff, DM
    [J]. VACCINE, 2005, 23 (08) : 977 - 983
  • [2] Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
    Andrews, N
    Borrow, R
    Miller, E
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (05) : 780 - 786
  • [3] BALMER P, 2004, EXPERT REV VACCINES, V3, P89
  • [4] THE EPIDEMIOLOGY OF INFECTIONS DUE TO NEISSERIA-MENINGITIDIS AND NEISSERIA-LACTAMICA IN A NORTHERN NIGERIAN COMMUNITY
    BLAKEBROUGH, IS
    GREENWOOD, BM
    WHITTLE, HC
    BRADLEY, AK
    GILLES, HM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1982, 146 (05) : 626 - 637
  • [5] du Chatelet IP, 2005, CLIN INFECT DIS, V40, P17, DOI 10.1086/426436
  • [6] Emergence of W135 meningococcal meningitis in Ghana
    Forgor, AA
    Leimkugel, J
    Hodgson, A
    Bugri, A
    Dangy, JP
    Gagneux, S
    Smith, T
    Pluschke, G
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2005, 10 (12) : 1229 - 1234
  • [7] HUMAN IMMUNITY TO MENINGOCOCCUS .2. DEVELOPMENT OF NATURAL IMMUNITY
    GOLDSCHNEIDER, I
    GOTSCHLICH, EC
    ARTENSTEIN, MS
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1969, 129 (06) : 1327 - +
  • [8] HOLTEN E, 1970, Scandinavian Journal of Infectious Diseases, V2, P201, DOI 10.3109/inf.1970.2.issue-3.08
  • [9] Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitidis in West Africa
    Kwara, A
    Adegbola, RA
    Corrah, PT
    Weber, M
    Achtman, M
    Morelli, G
    Caugant, DA
    Greenwood, BM
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1998, 3 (09) : 742 - 746
  • [10] Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135
    Lal, G
    Balmer, P
    Joseph, H
    Dawson, M
    Borrow, R
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (02) : 272 - 279